Vaxcyte, Inc. $PCVX Holdings Boosted by Algert Global LLC

Algert Global LLC grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 41.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 515,343 shares of the company's stock after purchasing an additional 151,359 shares during the quarter. Vaxcyte makes up 0.4% of Algert Global LLC's portfolio, making the stock its 26th largest holding. Algert Global LLC owned about 0.35% of Vaxcyte worth $29,957,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in PCVX. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock worth $30,000 after acquiring an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock worth $34,000 after acquiring an additional 184 shares during the period. CIBC Private Wealth Group LLC lifted its position in Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company's stock valued at $49,000 after purchasing an additional 1,350 shares during the last quarter. Finally, Capital Advisors Ltd. LLC bought a new stake in Vaxcyte in the 1st quarter valued at about $58,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. Wall Street Zen upgraded shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Vaxcyte in a research report on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the transaction, the chief financial officer directly owned 104,395 shares of the company's stock, valued at $5,979,745.60. The trade was a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 22,461 shares of the business's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the completion of the sale, the chief executive officer owned 474,703 shares in the company, valued at approximately $24,921,907.50. This trade represents a 4.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 120,646 shares of company stock valued at $6,570,810 in the last three months. 3.30% of the stock is currently owned by insiders.

Vaxcyte Price Performance

Vaxcyte stock opened at $61.87 on Tuesday. Vaxcyte, Inc. has a 12-month low of $29.87 and a 12-month high of $65.00. The stock has a market capitalization of $9.21 billion, a PE ratio of -8.11 and a beta of 1.23. The firm has a 50 day simple moving average of $56.67 and a 200-day simple moving average of $55.84.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the firm posted ($1.22) EPS. On average, analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source